Tag
The CONNECT trial demonstrates that continuous glucose monitoring (CGM) significantly improves glycemic control in adults with non-insulin-treated type 2 diabetes managed in primary care, reducing HbA1c levels and hyperglycemia risk without
The twiist AID system significantly improves glycemic control and patient satisfaction in insulin-treated type 2 diabetes over 13 weeks, demonstrating safety and effectiveness supported by complementary real-world and RCT data.
Continuous glucose monitoring-guided insulin optimization improves glycemic control and nutritional status in insulin-treated adults receiving long-term nocturnal parenteral nutrition, reducing hyperglycemia and associated complications.
A novel CGM-derived disposition index reliably estimates beta cell function in individuals with islet autoimmunity without insulin therapy, predicting glycemic deterioration one year later.
A randomized trial demonstrates that adding the digital therapeutic glucura to intermittent CGM and standard care significantly improves HbA1c, weight loss, and mental health in non-insulin-treated type 2 diabetes patients over six months.
A 6-month RCT in non-insulin-treated type 2 diabetes demonstrates that combining the digital therapeutic glucura with CGM significantly improves HbA1c, weight, and patient well-being beyond CGM and standard care alone.
In early pregnancy, adding oral glucose tolerance testing or continuous glucose monitoring to clinical factors improves prediction of gestational diabetes mellitus but not large-for-gestational-age births.
A 5-year real-world cohort study reveals that declines in CGM-derived time in range correlate with increased microvascular complications in type 1 diabetes, offering prognostic value beyond HbA1c.
This study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualize
This review examines the role of FreeStyle Libre Pro iQ CGM in differentiating presymptomatic stages of type 1 diabetes and predicting progression to clinical disease, comparing its performance with Dexcom G6 and discussing implications for
This 12-month analysis in adults with type 1 diabetes using advanced diabetes technology reveals that fear and perceived hypoglycemia frequency do not straightforwardly relate to continuous glucose monitoring metrics, highlighting complex d
This study demonstrates that initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in children and adolescents with cystic fibrosis improves continuous glucose monitoring (CGM) metrics, correlating with better clinical outcomes.
This review synthesizes evidence on daily and weekly patterns of glycemic control in real-world CGM data, highlighting small but consistent temporal variations that inform personalized diabetes care.
Experience-based continuous glucose monitoring (CGM) curricula significantly improve internal medicine residents’ confidence in applied patient care skills compared to traditional approaches, supporting hands-on CGM training integrati
This study reveals significant HbA1c and glucose discrepancies, especially in Black individuals, and introduces a personalized HbA1c correction (pA1C) that enhances diabetes management across racial groups.
Suspension of prior authorization requirements led to increased access to CGM and insulin pumps and significant HbA1c improvement in type 1 diabetes patients in a safety net clinic, highlighting benefits of reducing administrative barriers.
Dexcom buys Nutrisense and updates Stelo app with AI; Insulet lowers Omnipod 5 target to 100 mg/dL; Beta Bionics shares real-world iLet HbA1c data.
A population-based study reveals a significant reduction in impaired awareness of hypoglycemia and severe hypoglycemia in youth with type 1 diabetes from 2002 to 2024, indicating substantial progress in diabetes care and the ongoing need fo
This study demonstrates that continuous glucose monitoring-derived time in range (TIR) is independently associated with progression of arterial stiffness in type 2 diabetes, highlighting TIR as a valuable metric beyond HbA1c for cardiovascu
Among U.S. veterans with diabetes on dialysis, continuous glucose monitoring (CGM) use was associated with significantly lower mortality risk compared to non-CGM use, highlighting CGM’s potential to improve survival in this high-risk
